CA3117867A1 - Immunogenic compositions - Google Patents
Immunogenic compositions Download PDFInfo
- Publication number
- CA3117867A1 CA3117867A1 CA3117867A CA3117867A CA3117867A1 CA 3117867 A1 CA3117867 A1 CA 3117867A1 CA 3117867 A CA3117867 A CA 3117867A CA 3117867 A CA3117867 A CA 3117867A CA 3117867 A1 CA3117867 A1 CA 3117867A1
- Authority
- CA
- Canada
- Prior art keywords
- pertussis
- immunogenic composition
- toxoid
- omvs
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18204691 | 2018-11-06 | ||
| EP18204691.2 | 2018-11-06 | ||
| PCT/EP2019/080120 WO2020094580A1 (en) | 2018-11-06 | 2019-11-04 | Immunogenic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3117867A1 true CA3117867A1 (en) | 2020-05-14 |
Family
ID=64456746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3117867A Pending CA3117867A1 (en) | 2018-11-06 | 2019-11-04 | Immunogenic compositions |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12128094B2 (enExample) |
| EP (1) | EP3876982A1 (enExample) |
| JP (1) | JP7469302B2 (enExample) |
| KR (1) | KR102852282B1 (enExample) |
| CN (1) | CN112996538B (enExample) |
| AR (1) | AR117191A1 (enExample) |
| AU (1) | AU2019376832B2 (enExample) |
| BR (1) | BR112021007668A2 (enExample) |
| CA (1) | CA3117867A1 (enExample) |
| EA (1) | EA202190914A1 (enExample) |
| IL (1) | IL282753B2 (enExample) |
| MX (1) | MX2021005303A (enExample) |
| SG (1) | SG11202103389WA (enExample) |
| WO (1) | WO2020094580A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240082379A1 (en) | 2020-12-11 | 2024-03-14 | Glaxosmithkline Biologicals Sa | Hyper-Blebbing Bacteria |
| GB202211033D0 (en) | 2022-07-28 | 2022-09-14 | Glaxosmithkline Biologicals Sa | Purification process |
| CN119524117B (zh) * | 2025-01-23 | 2025-09-23 | 康希诺生物股份公司 | 免疫原性组合物、百白破联合疫苗及其制备方法和应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
| ATE127347T1 (de) | 1989-04-28 | 1995-09-15 | Sclavo Spa | Pertussistoxin-mutanten, dieselbe produzierende bordetella-stämme und ihre verwendung als vakzin gegen pertussis. |
| IT1248735B (it) * | 1990-06-21 | 1995-01-26 | Sclavo Spa | Vaccini acellulari contro la pertosse |
| KR100629028B1 (ko) | 1998-10-16 | 2006-09-26 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 애쥬번트 시스템 및 백신 |
| WO2000046147A2 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| EP1034792A1 (en) | 1999-03-11 | 2000-09-13 | Pasteur Merieux Serums Et Vaccins | Intranasal delivery of pneumococcal polysaccharide vaccines |
| FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
| DE60039450D1 (de) | 1999-12-02 | 2008-08-21 | Novartis Vaccines & Diagnostic | Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung |
| NO20002828D0 (no) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
| RU2323002C2 (ru) | 2001-07-26 | 2008-04-27 | Чирон Срл. | Вакцины, содержащие алюминиевые адъюванты и гистидин |
| US20060057160A1 (en) | 2002-08-02 | 2006-03-16 | Ralph Biemans | Vaccine composition |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
| ES3018133T3 (en) * | 2011-11-30 | 2025-05-14 | Univ Emory | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| BR112014014950B1 (pt) * | 2011-12-21 | 2022-03-29 | Bionet-Asia, Co. Ltd | Cepa de bordetella pertussis geneticamente modificada, e, métodos para produzir uma cepa de bordetella pertussis modificada e para produzir antígenos de bordetella pertussis |
| RU2015106791A (ru) * | 2012-10-03 | 2016-11-20 | Глэксосмитиклайн Байолоджикалз Са | Иммуногенные композиции |
| WO2014135651A1 (en) | 2013-03-08 | 2014-09-12 | Crucell Holland B.V. | Acellular pertussis vaccine |
| AR090538A1 (es) * | 2013-03-27 | 2014-11-19 | Consejo Nac Invest Cient Tec | Vacuna para la prevencion de infecciones con bordetella |
| MX2016001695A (es) | 2013-08-05 | 2016-05-02 | Glaxosmithkline Biolog Sa | Composiciones inmunogenas de combinacion. |
| JP2020500552A (ja) * | 2016-11-23 | 2020-01-16 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のウイルスによる送達方法 |
| ES2992907T3 (en) | 2017-03-13 | 2024-12-19 | Intravacc B V | Bordetella vaccines comprising lps with reduced reactogenicity |
-
2019
- 2019-11-04 IL IL282753A patent/IL282753B2/en unknown
- 2019-11-04 CN CN201980072018.3A patent/CN112996538B/zh active Active
- 2019-11-04 AU AU2019376832A patent/AU2019376832B2/en active Active
- 2019-11-04 AR ARP190103212A patent/AR117191A1/es unknown
- 2019-11-04 MX MX2021005303A patent/MX2021005303A/es unknown
- 2019-11-04 BR BR112021007668-9A patent/BR112021007668A2/pt unknown
- 2019-11-04 CA CA3117867A patent/CA3117867A1/en active Pending
- 2019-11-04 US US17/287,268 patent/US12128094B2/en active Active
- 2019-11-04 WO PCT/EP2019/080120 patent/WO2020094580A1/en not_active Ceased
- 2019-11-04 EP EP19805546.9A patent/EP3876982A1/en active Pending
- 2019-11-04 EA EA202190914A patent/EA202190914A1/ru unknown
- 2019-11-04 KR KR1020217016698A patent/KR102852282B1/ko active Active
- 2019-11-04 SG SG11202103389WA patent/SG11202103389WA/en unknown
- 2019-11-04 JP JP2021523667A patent/JP7469302B2/ja active Active
-
2024
- 2024-09-24 US US18/894,961 patent/US20250049906A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019376832B2 (en) | 2024-01-25 |
| IL282753A (en) | 2021-06-30 |
| MX2021005303A (es) | 2021-07-07 |
| JP2022506347A (ja) | 2022-01-17 |
| US20230201325A1 (en) | 2023-06-29 |
| US20250049906A1 (en) | 2025-02-13 |
| CN112996538B (zh) | 2025-07-08 |
| US12128094B2 (en) | 2024-10-29 |
| KR102852282B1 (ko) | 2025-09-01 |
| IL282753B2 (en) | 2025-04-01 |
| JP7469302B2 (ja) | 2024-04-16 |
| AU2019376832A1 (en) | 2021-05-13 |
| EA202190914A1 (ru) | 2021-08-03 |
| KR20210090646A (ko) | 2021-07-20 |
| SG11202103389WA (en) | 2021-05-28 |
| EP3876982A1 (en) | 2021-09-15 |
| BR112021007668A2 (pt) | 2021-07-27 |
| AR117191A1 (es) | 2021-07-21 |
| IL282753B1 (en) | 2024-12-01 |
| CN112996538A (zh) | 2021-06-18 |
| WO2020094580A1 (en) | 2020-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250049906A1 (en) | Immunogenic compositions | |
| US10603369B2 (en) | Combination vaccines with lower doses of antigen and/or adjuvant | |
| EA016417B1 (ru) | Способ получения вакцины | |
| JP6266631B2 (ja) | 免疫原性組成物 | |
| TWI630915B (zh) | 無細胞百日咳疫苗 | |
| EP2547357A1 (en) | Adjuvanted vaccines for serogroup b meningococcus | |
| JP7650871B2 (ja) | 免疫原性組成物 | |
| AU2009289059A1 (en) | Outer membrane vesicle prime - protein boost vaccine | |
| CA2894260A1 (en) | Conjugates for protecting against diphtheria and/or tetanus | |
| JP2008515842A (ja) | 混合ワクチン | |
| EA045827B1 (ru) | Иммуногенные композиции | |
| EA048463B1 (ru) | Иммуногенные композиции |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231025 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241104 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241104 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241104 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241127 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250324 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250325 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251022 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251022 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260401 |